Sequenom posted a net loss of $9.3m (£5.8m) for the second quarter, an huge improvement over the $15m loss a year ago.
The genetics technology product company reported revenue of $7.7m (£4.8m), which was the same as the quarter a year ago, with $7.3m (£4.5m) from its Genetic Systems business unit in the most recent quarter, and about $300,000 (£185,983) in revenue from the Pharmaceuticals unit.
By submitting your personal information, you agree that TechTarget and its partners may contact you regarding relevant content, products and special offers.
Those figures compare with $4.2m in Genetic Systems revenue a year ago and $3.5m in Pharmaceuticals for that period.
The drop in Pharmaceuticals revenue owing to a shift in the company's strategy, focusing more on internal discovery work and foregoing low-margin genotyping services.
Those units had operating losses of $3.6m (£2.2m) in Genetic Systems, compared with $7.9m last year, and $6.6m (£4.1m) in Pharmaceuticals compared with $8.2m a year ago. Both units had lower costs and expenses in the most recent quarter.
The company's total costs and expenses dropped to $17.8m (£11m) from $23.7m a year ago, mainly because of research programme completions and Sequenom closed sites in Europe and the US obtained through acquisitions.
For the six-month period ending 30 June, the company had a net loss of $17.9m, compared with $142.9m a year ago. Excluding charges of $116.9m, Sequenom had a $26m net loss for the second quarter of this year.
Nancy Weil writes for IDG News Service